Form D · Biotechnology
SkinJect, Inc.
Pittsburgh, PA · CIK 0001640615
Offering snapshot reported Jul 30, 2021 · SEC filing
- Reported sold
- $895K Offering amount: $1.5M
- Investors reported
- 11 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jul 15, 2021 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jul 30, 2021 | Initial | $895,091 | No comparison | 11 | SEC filing |
| May 30, 2019 | Initial | $2,500,000 | No comparison | 13 | SEC filing |
| Mar 30, 2017 | Initial | Yet to sell | No comparison | 0 | SEC filing |
| Dec 18, 2015 | Amendment | $500,000 | No comparison | 8 | SEC filing |
| May 12, 2015 | Initial | Yet to sell | No comparison | 0 | SEC filing |
Offering details
- Securities
- Other
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-408310
Convertible Notes
Source: Form D, filed Jul 30, 2021. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Joseph Donnelly | Director, Executive |
| Michael Fare | Director, Executive |
| Anthony Florence | Director, Promoter |
| Kenneth Melani | Director, Executive |
| James Nolan | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
285 Kappa Drive Suite 100
Pittsburgh, PA, 15238
Pittsburgh, PA, 15238